Verona Pharma plc (NASDAQ:TARA) has earned an average broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company. Verona Pharma’s rating score has improved by 14.2% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Analysts have set a 1-year consensus target price of $45.00 for the company, according to Zacks. Zacks has also assigned Verona Pharma an industry rank of 80 out of 255 based on the ratings given to its competitors.
TARA has been the subject of several recent research reports. LADENBURG THALM/SH SH started coverage on shares of Verona Pharma in a research note on Wednesday, January 22nd. They set a “buy” rating and a $45.00 target price for the company. ValuEngine upgraded shares of Verona Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th.
Shares of TARA traded up $0.62 during mid-day trading on Friday, hitting $36.87. 23,700 shares of the company’s stock were exchanged, compared to its average volume of 20,930. Verona Pharma has a fifty-two week low of $8.80 and a fifty-two week high of $157.60. The company has a market capitalization of $213.04 million, a price-to-earnings ratio of -0.96 and a beta of 0.47.
Verona Pharma Company Profile
ArTara Therapeutics, Inc develops rare diseases therapeutics for patients suffering from gastrointestinal, metabolic, circulatory, and neurological disorders. It offers IV Choline Chloride, a drug for the orphan disease intestinal failure associated liver disease (IFALD). The company was incorporated in 2017 and is headquartered in New York, New York.
Further Reading: Dividend Achievers
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.